Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

Nicola Curtin, Yvette Drew, Sweta Sharma Saha

Research output: Contribution to journalArticlepeer-review

Abstract

BRCA1/2 mutations and poly (ADP-ribose) polymerase (PARP) inhibitors are paradigmatic of synthetic lethal therapy. However, the activity of PARP inhibitors seems to vary considerably across BRCA1/2-mutant cancers and new insights into the tumour-lineage dependency of this synthetic lethal relationship might explain why BRCA1/2 mutations are not tumour-agnostic biomarkers of a response to PARP inhibitors.
Original languageEnglish
Pages (from-to)725–726
JournalNature Reviews Clinical Oncology
Volume16
DOIs
Publication statusPublished - 3 Oct 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy'. Together they form a unique fingerprint.

Cite this